The Technical Analyst
DiaMedica Therapeutics [DMAC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
DiaMedica Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.44% $2.51
America/New_York / 25 apr 2024 @ 11:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 95.27 mill |
| EPS: | -0.600 |
| P/E: | -4.18 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 37.96 mill |
| Avg Daily Volume: | 0.0398 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.18 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.71x |
| Company: PE -4.18 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.127 (-94.93%) $-2.38 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.31 - 2.71 ( +/- 7.93%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-22 | Lorianne Masuoka K. | Buy | 285 000 | Stock option (right to buy) |
| 2024-01-22 | Lorianne Masuoka K. | Buy | 0 | |
| 2024-01-02 | Semba Charles Pauling | Buy | 9 375 | Voting Common Shares, no par value per share |
| 2024-01-02 | Kuntz Richard | Buy | 14 285 | Voting Common Shares, no par value per share |
| 2024-01-02 | Pilnik Richard D. | Buy | 30 357 | Voting Common Shares, no par value per share |
| INSIDER POWER |
|---|
| 53.02 |
| Last 91 transactions |
| Buy: 8 059 792 | Sell: 2 870 847 |
Forecast:
13:45 - $2.49
Live Trading Signals (every 1 min)
Forecast
1: 12:15 - $2.52
Forecast 2: 13:05 - $2.49
Forecast 3: 13:45 - $2.49
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.51 (2.44% ) |
| Volume | 0.0035 mill |
| Avg. Vol. | 0.0398 mill |
| % of Avg. Vol | 8.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DMAC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Latest Press Releases
2024-04-17 16:08:00 - Press Release
Diamedica Therapeutics Announces First Patient Dosed In Relaunch Of Its Pivotal Phase 2/3 Remedy2 Trial Of Dm199 For The Treatment Of Acute Ischemic Stroke
Minneapolis--(business wire)--diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today announced the first patient being dosed in diamedica's relaunch of its pivotal phase 2/3 remedy2 trial of dm199 for the treatment of acute ischemic stroke. the company continues to work closely with its contract research organization (cro), on re-engaging with study sites for the rem.
2024-03-19 16:15:00 - Press Release
Diamedica Therapeutics Provides A Business Update And Announces Full Year 2023 Financial Results
Minneapolis--(business wire)--diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended december 31, 2023. management will host a conference call wednesday, march 20, 2024, at 8:00 am eastern time / 7:00 am central time to discuss its business update and full year 2023 financial results. remedy2 phase 2.
2024-01-29 16:13:00 - Press Release
Diamedica Therapeutics Announces Poster Presentation At International Stroke Conference
Minneapolis--(business wire)--diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company currently focused on developing recombinant klk1 (dm199) for the treatment of acute ischemic stroke (ais), today announced a poster presentation of the design and rationale for remedy2, the planned pivotal phase 2/3 trial of dm199 in ais patients, at the american heart association 2024 international stroke conference being held in phoenix, az from february 7 – 9, 2024. for inform.
2024-01-22 08:23:00 - Press Release
Diamedica Therapeutics Appoints Dr. Lorianne Masuoka As Chief Medical Officer
Minneapolis--(business wire)--diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of lorianne masuoka, m.d. as chief medical officer. dr. masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. “we.
2023-11-13 16:28:00 - Press Release
Diamedica Therapeutics Provides A Business Update And Announces Third Quarter 2023 Financial Results
Minneapolis--(business wire)--diamedica therapeutics inc. (nasdaq: dmac), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended september 30, 2023. management will host a conference call tuesday, november 14, 2023, at 8:00 am eastern time / 7:00 am central time to discuss its business update and third quarter 2023 financial results. remedy.
Latest News
2024-04-18 11:10:27 - Zacks Investment Research
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.
2024-04-15 10:36:10 - Zacks Investment Research
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2024-03-23 06:00:00 - InvestorPlace
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of the analysts' favorite penny stocks.
2024-03-19 21:53:17 - InvestorPlace
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents.
2023-11-14 12:10:06 - Seeking Alpha
DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer. Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call.
2023-08-31 11:17:44 - Zacks Investment Research
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.
2023-08-15 15:43:02 - Seeking Alpha
DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Capital Group Dan Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
2023-08-08 08:32:00 - Business Wire
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th. DiaMedica will host a live conference call on Tuesday, August 15th at 7:00 AM Central Time to provide a business update and discuss financial results. Co.
2023-05-16 09:11:05 - Seeking Alpha
DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.
2023-05-08 08:50:00 - Business Wire
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its first quarter 2023 financial results will be released after the markets close on Monday, May 15th. DiaMedica will host a live conference call on Tuesday, May 16th at 7:00 AM Central Time to provide a business update and discuss financial results. Conferenc.